Volume 379, Issue 9818, Pages (March 2012)

Slides:

Advertisements

Similar presentations

Please note, these are the actual video-recorded proceedings from the live CME event and may include the use of trade names and other raw, unedited content.

Advertisements

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Combination of Initial Palliative Prognostic Index and Score Change Provides a Better Prognostic Value for Terminally Ill Cancer Patients: A Six-Year.

Su K. Metcalfe, MD, MPH, Michael T

Volume 389, Issue 10072, Pages (March 2017)

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non–small cell lung cancer Babatunde A. Yerokun, MD, Chi-Fu.

Volume 79, Issue 1, Pages (January 2013)

Volume 376, Issue 9747, Pages (October 2010)

Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma Chi-Fu Jeffrey Yang, MD, Hanghang Wang, MD, PhD, Arvind.

Volume 385, Issue 9984, Pages (June 2015)

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Volume 11, Issue 4, Pages (April 2012)

Volume 376, Issue 9734, Pages (July 2010)

Volume 389, Issue 10069, Pages (February 2017)

Volume 13, Issue 12, Pages (December 2012)

Volume 376, Issue 9734, Pages (July 2010)

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Ultrasound-guided high-intensity focused ultrasound ablation for adenomyosis: the clinical experience of a single center Min Zhou, M.D., Ph.D., Jin-Yun.

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.

Prognostic signature of early lung adenocarcinoma based on the expression of ribonucleic acid metabolism–related genes Ruben Pio, PharmD, PhD, Jackeline.

Volume 12, Issue 3, Pages (March 2011)

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy Apar Pataer, MD, PhD, Neda Kalhor,

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer Hong.

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Relationship Between Tumor Size and Survival in Non–Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER)

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Volume 390, Issue 10094, Pages (August 2017)

Volume 18, Issue 3, Pages (March 2017)

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Volume 13, Issue 12, Pages (December 2012)

Volume 385, Issue 9984, Pages (June 2015)

Conditional Cancer-Specific Versus Cardiovascular-Specific Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Shawn S. Groth, MD, MS, Natasha.

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

Photodynamic Therapy for Early Stage Central Type of Lung Cancer

Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: Results from the ACOSOG Z4032 (Alliance) multicenter randomized.

Standard Outcome Measures for Thymic Malignancies

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Volume 373, Issue 9666, Pages (March 2009)

Volume 18, Issue 3, Pages (March 2017)

EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer Sarita Dubey, MD, Patricia Stephenson, ScD, Donna E. Levy,

Validation of a Molecular and Pathological Model for Five-Year Mortality Risk in Patients with Early Stage Lung Adenocarcinoma Raphael Bueno, MD, Elisha.

All-cause mortality risk associated with long-term exposure to ambient PM2·5 in China: a cohort study Prof Tiantian Li, PhD, Yi Zhang, MPH, Jiaonan Wang,

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

Volume 378, Issue 9786, Pages (July 2011)

Survival After Surgery for Pathologic Stage IA Non-Small Cell Lung Cancer Associated With Idiopathic Pulmonary Fibrosis Yuichi Saito, MD, Yasuyuki Kawai,

Andrew P. Dhanasopon, MD, Michelle C. Salazar, MD, Jessica R

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Department of Error The Lancet Volume 369, Issue 9564, (March 2007)

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma Kyuichi Kadota, MD, PhD, Jun-ichi Nitadori, MD, PhD, Hideki Ujiie, MD, Daniel.

High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma Yong Li, MD, Hao-Xian Yang, MD, Rong-Zhen.

Volume 373, Issue 9672, Pages (April 2009)

Volume 376, Issue 9747, Pages (October 2010)

Refining the Nodal Staging for Esophageal Squamous Cell Carcinoma Based on Lymph Node Stations Jun Peng, MD, Wen-Ping Wang, MD, Ting Dong, MD, Jie Cai,

Volume 366, Issue 9494, Pages (October 2005)

Carcinoma of the esophagus: Prognostic significance of histologic type

Identification and Validation of Lymphovascular Invasion as a Prognostic and Staging Factor in Node-Negative Esophageal Squamous Cell Carcinoma Qingyuan.

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Volume 14, Issue 7, Pages (June 2013)

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Volume 20, Issue 8, Pages (August 2019)

Presentation transcript:

Volume 379, Issue 9818, Pages 823-832 (March 2012) A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies Johannes R Kratz, MD, Prof Jianxing He, MD, Stephen K Van Den Eeden, PhD, Prof Zhi-Hua Zhu, MD, Prof Wen Gao, MD, Patrick T Pham, BS, Michael S Mulvihill, BS, Fatemeh Ziaei, BS, Huanrong Zhang, MD, Bo Su, MD, Prof Xiuyi Zhi, MD, Charles P Quesenberry, PhD, Laurel A Habel, BS, Qiuhua Deng, BS, Zongfei Wang, BS, Jiangfen Zhou, BS, Huiling Li, PhD, Mei-Chun Huang, PhD, Che-Chung Yeh, PhD, Prof Mark R Segal, PhD, M Roshni Ray, BS, Prof Kirk D Jones, MD, Dan J Raz, MD, Zhidong Xu, MD, Thierry M Jahan, MD, David Berryman, PharmD, Biao He, PhD, Dr Michael J Mann, MD, Prof David M Jablons, MD The Lancet Volume 379, Issue 9818, Pages 823-832 (March 2012) DOI: 10.1016/S0140-6736(11)61941-7 Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 1 Probability of mortality and mortality hazard ratio by subgroup in the training cohort Probability of mortality at 5 years by risk score; dashed lines are 95% CIs, hash marks above the x axis are individual risk scores for every patient. (B) Increase in 5 year overall mortality hazard ratio (HR) by subgroup for each stepwise increase in risk category (eg, low to intermediate, and intermediate to high); box sizes are proportional to group size. A hazard ratio greater than 1 implies that more patients in the high-risk group are dying at any time compared with the low-risk group; a hazard ratio of less than 1 means that fewer patients in the high-risk group are dying at any time compared with the low-risk group. AJCC=American Joint Committee on Cancer.22 The Lancet 2012 379, 823-832DOI: (10.1016/S0140-6736(11)61941-7) Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 2 Survival analysis by risk category in the Kaiser Permanente validation cohort (A) Overall survival for the entire cohort; median survival was 113 months in the low-risk group, 91 months in the intermediate-risk group, and 59 months in the high-risk group. (B) Lung-cancer-specific survival for the entire cohort (non-lung cancer deaths were censored); median lung cancer-specific survival was not reached in any risk group; the mortality incidence rate was 2·7 per 100 person-years in the low-risk group, 5·0 per 100 person-years in the intermediate-risk group, and 6·6 per 100 person-years in the high-risk group. (C) Overall survival for 330 patients with American Joint Commission on Cancer stage IA and IB disease considered to be low risk as per conventional pathological criteria (National Comprehensive Cancer Network); median survival was 113 months in the low-risk group, 88 months in the intermediate-risk group, and 70 months in the high-risk group. The Lancet 2012 379, 823-832DOI: (10.1016/S0140-6736(11)61941-7) Copyright © 2012 Elsevier Ltd Terms and Conditions

Figure 3 Survival analysis by risk category in the China Clinical Trials Consortium validation cohort (A) Overall survival for the entire cohort. Survival in patients with stage I (B) stage II (C) and stage III (D) disease. The Lancet 2012 379, 823-832DOI: (10.1016/S0140-6736(11)61941-7) Copyright © 2012 Elsevier Ltd Terms and Conditions